Stocktoria
electroCore, Inc. ECOR
electroCore, Inc. (ECOR) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $32.0M at a -43.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ECOR | electroCore, Inc. | 4/9 | — | — | +27.2% |
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
| POCI | PRECISION OPTICS CORPORATION, INC. | 3/9 | -8.27 | — | -0.1% |
| QTI | QT IMAGING HOLDINGS, INC. | 5/9 | -4.34 | — | — |
| HYPR | Hyperfine, Inc. | 4/9 | -16.31 | — | +5.2% |
| CV | CapsoVision, Inc | 2/9 | — | — | +15.3% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About electroCore, Inc.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
FAQ
Is ECOR financially healthy?
electroCore, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ECOR pay a dividend?
No, electroCore, Inc. does not currently pay a dividend.
How profitable is ECOR?
In FY2025, electroCore, Inc. had a net margin of -43.6%.
What is the analyst price target for ECOR?
The average Wall-Street price target for electroCore, Inc. is $19.17, about 103.9% above the recent price, from 5 analysts (consensus: strong buy).
Is ECOR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on electroCore, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.